Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
Rubius Therapeutics, Inc. (RUBY)
Last rubius therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020. Dr. Turka, a distinguished physician-scientist in autoimmunity and translational immunology, joins Rubius from Rheos Medicines, where he was a co-founder and served as chief scientific officer. “Larry brings to Rubius exceptional insights and an extraordinary record of scientific achievement in immune-mediated diseases,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics. “Larry joins at a pivotal time as we continue to explore the broad potential of the RED PLATFORM® for the treatment of rare diseases, cancer and autoimmune diseases and as our lead oncology program, RTX-240, is expected to enter t
Show less
Read more
Impact Snapshot
Event Time:
RUBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RUBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RUBY alerts
High impacting Rubius Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics